References
- Murdan S. Organogels in drug delivery. Expert Opin Drug Deliv 2005;2:489–505
- Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 2004;58:445–55
- Vintiloiu A, Leroux JC. Organogels and their use in drug delivery – a review. J Control Release 2008;125:179–92
- Gao Z-H, Crowley WR, Shukla AJ, et al. Controlled release of contraceptive steroids from biodegradable and injectable gel formulations: in vivo evaluation. Pharm Res 1995;12:864–8
- Motulsky A, Lafleur M, Couffin-Hoarau AC, et al. Characterization and biocompatibility of organogels based on l-alanine for parenteral drug delivery implants. Biomaterials 2005;26:6242–53
- Terech P, Weiss RG. Low molecular mass gelators of organic liquids and the properties of their gels. Chem Rev 1997;97:3133–59
- Akers MJ, Fites AL, Robison RL. Formulation design and development of parenteral suspensions. J Parenter Sci Technol 1987;41:88–96
- Higuchi T. Some physical chemical aspects of suspension formulation. J Am Pharm Assoc 1958;47:657–60
- Nash R. Suspensions. In: James S, ed. Encyclopedia of pharmaceutical technology. 3rd ed. Chap. 259. New York: Informa Healthcare; 2006:3597–610
- Wong J, Brugger A, Khare A, et al. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv Drug Deliv Rev 2008;60:938–54
- Hall KS, Trussell J. Types of combined oral contraceptives used by US women. Contraception 2012;86:659–65
- Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29–38
- Nippe S, General S. Parenteral oil-based drospirenone microcrystal suspensions – evaluation of physicochemical stability and influence of stabilising agents. Int J Pharm 2011;416:181–8
- Tingstad JE. Physical stability testing of pharmaceuticals. J Pharm Sci 1964;53:955–62
- Crowder TM, Hickey AJ, Louey MD, Orr N. A guide to pharmaceutical particulate science. 4th ed. Boca Raton, London, New York, Washington, DC: Interpharm/CRC; 2003
- Boylan JC, Nail SL. Parenteral products. In: Banker GS, Rhodes CT, eds. Modern pharmaceutics. 4th ed. New York: Marcel Dekker, Inc.; 2002:576–625
- Nippe S, Preuβe C, General S. Evaluation of the in vitro release and pharmacokinetics of parenteral injectable formulations for steroids. Eur J Pharm Biopharm 2012;83:253–65
- Moore JW, Flanner HH. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharm Tech 1996;20:64–74
- Guidance for industry dissolution testing of immediate release solid oral dosage forms. Rockville (MD): US Food and Drug Administration; 1997. Available from: www.fda.gov [last accessed 21 Oct 2013]
- Rowe RC, Sheskey PJ, Weller PJ. Handbook of pharmaceutical excipients. 4th ed. London: Pharmaceutical Press; 2003
- Balasubramanian R, Sughir AA, Damodar G. Oleogel: a promising base for transdermal formulations. Asian J Pharm Sci 2012;6:1–9
- Mezger TG. The rheology handbook: for users of rotational and oscillatory rheometers. 2nd ed. Hannover: Vincentz Network GmbH&Co.KG; 2006
- Nutan MTH, Reddy IK. General principles of suspensions. In: Kulshreshtha AK, Singh ON, Wall GM, eds. Pharmaceutical suspensions from formulation development to manufacturing. New York, Dordrecht, Heidelberg, London: Springer; 2010:39–66
- Zuidema J, Kadir F, Titulaer HAC, Oussoren C. Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (II). Int J Pharm 1994;105:189–207
- St'astný M, Plocová D, Etrych T, et al. HPMA-hydrogels containing cytostatic drugs. Kinetics of the drug release and in vivo efficacy. J Control Release 2002;81:101–11
- Larsen SW, Larsen C. Critical factors influencing the in vivo performance of long-acting lipophilic solutions – impact on in vitro release method design. AAPS J 2009;11:762–70
- Gao Z-H, Shukla AJ, Johnson JR, Crowley WR. Controlled release of contraceptive steroids from biodegradable and injectable gel formulations: In vitro evaluation. Pharm Res 1995;12:857–63
- Rungseevijitprapa W, Siepmann F, Siepmann J, Paeratakul O. Disperse systems. In: Alexander TF, Juergen S, eds. Modern pharmaceutics: basic principles and systems. 5th ed. New York, London: Informa Healthcare; 2009:357–421
- Martinez M, Rathbone M, Burgess D, Huynh M. In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting. J Control Release 2008;129:79–87
- Antal EJ, Dick CF, Wright III CE, et al. Comparative bioavailability next term of two medroxyprogesterone acetate suspensions. Int J Pharm 1989;54:33–9
- Montgomery BSI, Borwell JP, Higgins DM. Does needle size matter? Patient experience of luteinising homone-releasing hormone analogie injection. Prostate Cancer Prostatic Dis 2005;8:66–8
- Scott Ricci S, Kyle T. Maternity and pediatric nursing. Philadelphia: Lippincott Wiliams & Wilkins; 2009
- Rungseevijitprapa W, Bodmeier R. Injectability of biodegradable in situ forming microparticle systems (ISM). Eur J Pharm Sci 2009;36:524–31
- Pisal PB, Patil SS, Pokharkar VB. Rheological investigation and its correlation with permeability coefficient of drug loaded carbopol gel: influence of absorption enhancers. Drug Dev Ind Pharm 2013;39:593–9